Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during β-lapachone-mediated apoptosis

Experimental Cell Research

Volumn 255, Issue 2, 2000, Pages 144-155

  Pink, John J ^a   Wuerzberger Davis, Shelly ^a,c   Tagliarino, Colleen ^a   Planchon, Sarah M ^a   Yang, XiaoHe ^b   Froelich, Christopher J ^b   Boothman, David A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Evanston NW Hlthcare Res Inst   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apoptosis; Breast cancer; Calpain; Caspase; PARP; Poly(ADP) ribose polymerase; Topotecan; lapachone

Indexed keywords

BETA LAPACHONE; CASPASE; CYSTEINE PROTEINASE; DNA TOPOISOMERASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL KILLING; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0034653956     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4790     Document Type: Article

References (57)

1. Alnemri E. S., Livingston D. J., Nicholson D. W., Salvesen G., Thornberry N. A., Wong W. W., Yuan J. Y. Human Ice/Ced-3 protease nomenclature. Cell. 87:1996;171.
2. Piedrafita F. J., Pfahl M. Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol. Cell. Biol. 17:1997;6348-6358.
3. Patel T., Gores G. J., Kaufmann S. H. The role of proteases during apoptosis. FASEB J. 10:1996;587-597.
4. Janicke R. U., Walker P. A., Lin X. Y., Porter A. G. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J. 15:1996;6969-6978.
5. An B., Dou Q. P. Cleavage of retinoblastoma protein during apoptosis: An interleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res. 56:1996;438-442.
6. Talanian R. V., Quinlan C., Trautz S., Hackett M. C., Mankovich J. A., Banach D., Ghayur T., Brady K. D., Wong W. W. Substrate specificities of caspase family proteases. J. Biol. Chem. 272:1997;9677-9682.
7. Kaufmann S. H., Desnoyers S., Ottaviano Y., Davidson N. E., Poirier G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: An early marker of chemotherapy-induced apoptosis. Cancer Res. 53:1993;3976-3985.
8. Wang X., Pai J. T., Wiedenfeld E. A., Medina J. C., Slaughter C. A., Goldstein J. L., Brown M. S. Purification of an interleukin-1 beta converting enzyme-related cysteine protease that cleaves sterol regulatory element-binding proteins between the leucine zipper and transmembrane domains. J. Biol. Chem. 270:1995;18044-18050.
9. Squier M. K., Miller A. C., Malkinson A. M., Cohen J. J. Calpain activation in apoptosis. J. Cell. Physiol. 159:1994;229-237.
10. Wood D. E., Thomas A., Devi L. A., Berman Y., Beavis R. C., Reed J. C., Newcomb E. W. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene. 17:1998;1069-1078.
11. Porn-Ares M. I., Samali A., Orrenius S. Cleavage of the calpain inhibitor, calpastatin, during apoptosis. Cell Death Differ. 5:1998;1028-1033.
12. Chandra J., Niemer I., Gilbreath J., Kliche K. O., Andreeff M., Freireich E. J., Keating M., McConkey D. J. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 92:1998;4220-4229.
13. McConkey D. J. Calcium-dependent, interleukin 1-converting enzyme inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei. J. Biol. Chem. 271:1996;22398-22406.
14. Shimizu T., Pommier Y. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: Effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia. 11:1997;1238-1244.
15. Marthinuss J., Andrade-Gordon P., Seiberg M. A secreted serine protease can induce apoptosis in Pam212 keratinocytes. Cell Growth Differ. 6:1995;807-816.
16. Yang X., Stennicke H. R., Wang B., Green D. R., Janicke R. U., Srinivasan A., Seth P., Salvesen G. S., Froelich C. J. Granzyme B mimics apical caspases. Description of a unified pathway for trans-activation of executioner caspase-3 and -7. J. Biol. Chem. 273:1998;34278-34283.
17. Boothman D. A., Trask D. K., Pardee A. B. Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I. Cancer Res. 49:1989;605-612.
18. Planchon S. M., Wuerzberger S., Frydman B., Witiak D. T., Hutson P., Church D. R., Wilding G., Boothman D. A. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response. Cancer Res. 55:1995;3706-3711.
19. Boothman D. A., Wang M., Schea R. A., Burrows H. L., Strickfaden S., Owens J. K. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys. 24:1992;939-948.
20. Li C. J., Averboukh L., Pardee A. B. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem. 268:1993;22463-22468.
21. Boothman D. A., Pardee A. B. Inhibition of radiation-induced neoplastic transformation by beta-lapachone. Proc. Natl. Acad. Sci. USA. 86:1989;4963-4967.
22. Nelson W. G., Kastan M. B. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1994;1815-1823.
23. Boothman D. A. Enhanced malignant transformation is accompanied by increased survival recovery after ionizing radiation in Chinese hamster embryo fibroblasts. Radiat. Res. 138:1994;S121-S125.
24. Wuerzberger S. M., Pink J. J., Planchon S. M., Byers K. L., Bornmann W. G., Boothman D. A. Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone. Cancer Res. 58:1998;1876-1885.
25. Frydman B., Marton L. J., Sun J. S., Neder K., Witiak D. T., Liu A. A., Wang H. M., Mao Y., Wu H. Y., Sanders M. M., Liu L. F. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. Cancer Res. 57:1997;620-627.
26. Larsen A. K., Skladanowski A., Bojanowski K. The roles of DNA topoisomerase II during the cell cycle. Prog. Cell. Cycle. Res. 2:1996;229-239.
27. D'Arpa P., Liu L. F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta. 989:1989;163-177.
28. Slevin M. L. The clinical pharmacology of etoposide. Cancer. 67:1991;319-329.
29. Jonsson E., Fridborg H., Csoka K., Dhar S., Sundstrom C., Nygren P., Larsson R. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br. J. Cancer. 76:1997;211-219.
30. Lamond J. P., Wang M., Kinsella T. J., Boothman D. A. Radiation lethality enhancement with 9-aminocamptothecin: Comparison to other topoisomerase I inhibitors. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;369-376.
31. Pink J. J., Bilimoria M. M., Assikis J., Jordan V. C. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br. J. Cancer. 74:1996;1227-1236.
32. Pink J. J., Jiang S. Y., Fritsch M., Jordan V. C. An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res. 55:1995;2583-2590.
33. Pink J. J., Jordan V. C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 56:1996;2321-2330.
34. Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102:1980;344-352.
35. Musgrove E. A., Sutherland R. L. Acute effects of growth factors on T-47D breast cancer cell cycle progression. Eur. J. Cancer. 29A:1993;2273-2279.
36. Musgrove E. A., Sutherland R. L. Steroids, growth factors, and cell cycle controls in breast cancer. Cancer Treat. Res. 53:1991;305-331.
37. Pink J. J., Fritsch M., Bilimoria M. M., Assikis V. J., Jordan V. C. Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line. Br. J. Cancer. 75:1997;17-27.
38. Lotem J., Sachs L. Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents. Proc. Natl. Acad. Sci. USA. 93:1996;12507-12512.
39. Li X., Traganos F., Melamed M. R., Darzynkiewicz Z. Single-step procedure for labeling DNA strand breaks with fluorescein- or BODIPY-conjugated deoxynucleotides: Detection of apoptosis and bromodeoxyuridine incorporation. Cytometry. 20:1995;172-180.
40. Zollner H. Handbook of Enzyme Inhibitors. 1993;VCH, Weinheim, New York. p. 728-730.
41. Waxman L. Calcium-activated proteases in mammalian tissues. Methods Enzymol. 80:1981;664-680.
42. Kubbutat M. H., Vousden K. H. Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol. Cell. Biol. 17:1997;460-468.
43. Pariat M., Carillo S., Molinari M., Salvat C., Debussche L., Bracco L., Milner J., Piechaczyk M. Proteolysis by calpains: A possible contribution to degradation of p53. Mol. Cell. Biol. 17:1997;2806-2815.
44. Wakeling A. E., Bowler J. ICI 182,780, a new antioestrogen with clinical potential. J. Steroid Biochem. Mol. Biol. 43:1992;173-177.
45. Pink J. J., Jordan V. C. Molecular mechanisms of antiestrogen resistance. Dickson R. B., Lippman M. E. Drug and Hormonal Resistance in Breast Cancer: Cellular and Molecular Mechanisms. 1995;Ellis Horwood, Hemel Hempstead.
46. Musgrove E. A., Sarcevic B., Sutherland R. L. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J. Cell. Biochem. 60:1996;363-378.
47. Musgrove E. A., Sutherland R. L. Cell cycle control by steroid hormones. Semin. Cancer Biol. 5:1994;381-389.
48. Musgrove E. A., Wakeling A. E., Sutherland R. L. Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res. 49:1989;2398-2404.
49. Foster J. S., Wimalasena J. Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol. Endocrinol. 10:1996;488-498.
50. Li F., Srinivasan A., Wang Y., Armstrong R. C., Tomaselli K. J., Fritz L. C. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J. Biol. Chem. 272:1997;30299-30305.
51. Orth K., Chinnaiyan A. M., Garg M., Froelich C. J., Dixit V. M. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J. Biol. Chem. 271:1996;16443-16446.
52. Takahashi A., Alnemri E. S., Lazebnik Y. A., Fernandes-Alnemri T., Litwack G., Moir R. D., Goldman R. D., Poirier G. G., Kaufmann S. H., Earnshaw W. C. Cleavage of lamin A by Mch2 alpha but not CPP32: Multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc. Natl. Acad. Sci. USA. 93:1996;8395-8400.
53. Morris E. J., Geller H. M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: Evidence for cell cycle-independent toxicity. J. Cell Biol. 134:1996;757-770.
54. Shah G. M., Shah R. G., Poirier G. G. Different cleavage pattern for poly(ADP-ribose) polymerase during necrosis and apoptosis in HL-60 cells. Biochem. Biophys. Res. Commun. 229:1996;838-844.
55. Faleiro L., Kobayashi R., Fearnhead H., Lazebnik Y. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J. 16:1997;2271-2281.
56. Hirata H., Takahashi A., Kobayashi S., Yonehara S., Sawai H., Okazaki T., Yamamoto K., Sasada M. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J. Exp. Med. 187:1998;587-600.
57. Planchon S. M., Wuerzberger-Davis S. M., Pink J. J., Robertson K. A., Bornmann W. G., Boothman D. A. Bcl-2 protects against β-lapachone-mediated caspase 3 activation and apoptosis in human myeloid leukemia (HL-60) cells. Oncol. Rep. 6:1999;485-492.